Can Huonslab crack oncology’s next drug-delivery problem? New patent targets injectable ADCs
Huonslab’s HyDIFFUZE patent targets subcutaneous ADC formulations, but preclinical evidence and clinical translation remain the real test.
Pharma & Biotech